Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Psychosis in Patients With Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs MP 101 Mediti Pharma (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Mediti Pharma
- 04 May 2017 Status changed from not yet recruiting to recruiting.
- 21 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
- 09 Feb 2017 New trial record